BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 11899505)

  • 1. [The use of albumin infusion in decompensated liver cirrhosis].
    Schmidt LE; Ring-Larsen H
    Ugeskr Laeger; 2002 Feb; 164(9):1196-202. PubMed ID: 11899505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of albumin in patients with decompensated cirrhosis: the case in favor.
    Maor Y
    Isr Med Assoc J; 2005 Feb; 7(2):115-8. PubMed ID: 15729966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of cirrhotic complications with human serum albumin].
    Henriksen JH; Ring-Larsen H
    Ugeskr Laeger; 2005 Jan; 167(4):414. PubMed ID: 15719571
    [No Abstract]   [Full Text] [Related]  

  • 4. Long-term clinical outcome of large volume paracentesis with intravenous albumin in patients with spontaneous bacterial peritonitis: a randomized prospective study.
    Choi CH; Ahn SH; Kim DY; Lee SK; Park JY; Chon CY; Moon YM; Han KH
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1215-22. PubMed ID: 16048569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites.
    Peltekian KM; Wong F; Liu PP; Logan AG; Sherman M; Blendis LM
    Am J Gastroenterol; 1997 Mar; 92(3):394-9. PubMed ID: 9068457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug insight: the role of albumin in the management of chronic liver disease.
    Wong F
    Nat Clin Pract Gastroenterol Hepatol; 2007 Jan; 4(1):43-51. PubMed ID: 17203088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
    Ginès P; Uriz J; Calahorra B; Garcia-Tsao G; Kamath PS; Del Arbol LR; Planas R; Bosch J; Arroyo V; Rodés J
    Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical indications for the albumin use: still a controversial issue.
    Caraceni P; Domenicali M; Tovoli A; Napoli L; Ricci CS; Tufoni M; Bernardi M
    Eur J Intern Med; 2013 Dec; 24(8):721-8. PubMed ID: 23790570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ascites in cirrhosis: a review of management and complications.
    Kuiper JJ; van Buuren HR; de Man RA
    Neth J Med; 2007 Sep; 65(8):283-8. PubMed ID: 17890787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites.
    Sola-Vera J; Miñana J; Ricart E; Planella M; González B; Torras X; Rodríguez J; Such J; Pascual S; Soriano G; Pérez-Mateo M; Guarner C
    Hepatology; 2003 May; 37(5):1147-53. PubMed ID: 12717396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of ascites in patients with end-stage liver disease.
    Saadeh S; Davis GL
    Rev Gastroenterol Disord; 2004; 4(4):175-85. PubMed ID: 15580152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Albumin: Indications in chronic liver disease.
    Tufoni M; Zaccherini G; Caraceni P; Bernardi M
    United European Gastroenterol J; 2020 Jun; 8(5):528-535. PubMed ID: 32213034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Albumin in decompensated liver cirrhosis].
    Gøtzche PC
    Ugeskr Laeger; 2002 Feb; 164(9):1203-4. PubMed ID: 11899507
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevention of paracentesis-induced circulatory dysfunction in cirrhosis: standard vs half albumin doses. A prospective, randomized, unblinded pilot study.
    Alessandria C; Elia C; Mezzabotta L; Risso A; Andrealli A; Spandre M; Morgando A; Marzano A; Rizzetto M
    Dig Liver Dis; 2011 Nov; 43(11):881-6. PubMed ID: 21741331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study comparing human albumin vs. reinfusion of ultrafiltrate-ascitic fluid after total paracentesis in cirrhotic patients with tense ascites.
    Zaak D; Paquet KJ; Kuhn R
    Z Gastroenterol; 2001 Jan; 39(1):5-10. PubMed ID: 11215366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin infusion in liver cirrhotic patients.
    Rena NM; Wibawa ID
    Acta Med Indones; 2010 Jul; 42(3):162-8. PubMed ID: 20724771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis.
    Chen TA; Tsao YC; Chen A; Lo GH; Lin CK; Yu HC; Cheng LC; Hsu PI; Tsai WL
    Scand J Gastroenterol; 2009; 44(5):619-25. PubMed ID: 19191184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of human albumin for the treatment of ascites in patients with liver cirrhosis: item of safety, facts, controversies and perspectives.
    Facciorusso A; Nacchiero MC; Rosania R; Laonigro G; Longo N; Panella C; Ierardi E
    Curr Drug Saf; 2011 Sep; 6(4):267-74. PubMed ID: 22129322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials.
    Bernardi M; Caraceni P; Navickis RJ; Wilkes MM
    Hepatology; 2012 Apr; 55(4):1172-81. PubMed ID: 22095893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Advances in therapy for ascites and hepatorenal syndrome].
    Gerbes AL; Gülberg V
    Z Gastroenterol; 2005 Jan; 43(1):31-4. PubMed ID: 15650969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.